In 2025, investors are still interested in Agilent Technologies’ shares (NYSE: A). Agilent Technologies has established a solid reputation for innovation and reliable performance as an industry leader in the life sciences, diagnostics, and applied chemical sectors. However, is it better to buy, hold, or sell Agilent Technologies stock in the current market? We’ll go over everything an investor needs to know about Agilent Technologies stock in this in-depth guide, including the company’s background, growth potential, risks, and analyst ratings, so you can make wise choices.
Agilent Technologies: What Is It?
Leading the way in laboratory equipment and solutions worldwide is Agilent Technologies Inc. With its headquarters located in Santa Clara, California, the firm was established in 1999 as a spin-off from Hewlett-Packard (HP). Agilent offers consumables, software, services, and analytical tools for the whole laboratory process.
Among its principal marketplaces are:
-
Biotechnology and pharmaceuticals: instruments for quality assurance and medication development
-
Pathology lab solutions are included in diagnostics and genomics
-
Chemical and energy: industrial, petrochemical, and environmental process testing
-
Food and agriculture: quality control and contamination testing
Agilent Technologies’ stock benefits from demand in both established and new areas due to its diverse client base and applications.
Overview of Agilent Technologies’ Stock
The ticker “A” is used to identify Agilent Technologies on the New York Stock Exchange (NYSE). Agilent Technologies’ stock has shown growth and stability as of early 2025, making it attractive to both conservative portfolios and growth investors.
Important Stock Data (as of Q2 2025):
-
Ticker: A
-
Value of Market: Over $39 billion
-
P/E Ratio: around 28
-
Dividend Yield: ~0.8%
-
52-Week Range: $102 to $146
-
Beta: 1.03, indicating a moderate level of volatility
These figures show that, despite having great market presence and robust financial support, Agilent Technologies’ stock trades at a premium.
Past Performance of Stocks
An examination of Agilent Technologies’ stock over the last five years provides information on the company’s growth trajectory. The post-pandemic need for lab testing equipment and advancements in diagnostics drove the stock’s notable rise between 2020 and 2023. However, macroeconomic challenges including inflation and supply chain problems caused some minor volatility in the stock in 2024.
Long-term investors, however, have benefited:
-
Five-year compound annual growth rate (CAGR): around 12%
-
Growth in dividends: steady rises since 2012
-
Stock buybacks: Agilent has increased shareholder value via share repurchase programs
All things considered, Agilent Technologies’ stock’s long-term rising trajectory is a reflection of solid fundamentals and investor confidence.
The Reasons Behind Investor Interest in Agilent Technologies Stock
1. A Solid Position in the Market
Leading positions in mass spectrometry, liquid chromatography, and molecular diagnostics—all essential instruments for academic and pharmaceutical research—are held by Agilent. It has pricing power and a competitive edge because of its leadership.
2. Model of Recurring Revenue
Consumables and services account for a significant amount of Agilent’s business, guaranteeing stronger margins and recurring revenue. This company approach lessens revenue cyclicality and increases predictability.
3. Investment in R&D
Agilent spends more than $400 million a year on research and development (R&D) in order to stay ahead of the competition and innovate. This emphasis on innovation is encouraging for future expansion.
4. The Growing Healthcare Industry
The need for diagnostics and life sciences tools is rising due to aging populations and expanding healthcare requirements worldwide, which will support Agilent Technologies’ stock’s long-term growth.
Financials and Earnings of Agilent Technologies
Agilent said in its most recent financial report (Q2 FY2025):
-
$1.78 billion in revenue, up 4% year over year
-
$295 million is the net income
-
EPS: adjusted to $1.08
-
Cash Flow Free: $310 million
-
Margin of Gross: about 56%
Agilent often reports profitable results with high margins and free cash flow. With more than $1.5 billion in cash on hand and acceptable debt levels, analysts point out that the corporation has a healthy balance sheet.
Challenges and Risks for the Stock of Agilent Technologies
Despite Agilent Technologies’ stock’s numerous advantages, it’s crucial to weigh the dangers before making an investment:
1. Sensitivity to the Economy
Customers of Agilent, particularly those in business and academics, could reduce their expenditures during recessions. Despite the steady need for healthcare, funding for research might fluctuate.
2. Changes in Currency
Agilent is exposed to FX risks due to its worldwide operations. International revenues might lose value due to a high U.S. currency.
3. Rivalry
Companies like as Waters Corporation (WAT), Danaher Corporation (DHR), and Thermo Fisher Scientific (TMO) are competitors of Agilent. Competitors’ aggressive pricing or technical advancements may have an effect on market share.
4. Hazards Associated with Regulation
Agilent’s medical testing and diagnostics divisions may be impacted by changes to healthcare laws or product approvals.
Price Projections and Analyst Ratings
Analysts typically rank Agilent Technologies’ stock as a “Moderate Buy” as of June 2025. Among 20 analysts on Wall Street:
-
10 Give it a “Buy” rating
-
8 Give it a “Hold” rating
-
2 Give it a “Sell” rating
Summary of the Price Target:
-
12-month average goal: $144
-
High goal: $160
-
Low goal: $110
Because of Agilent Technologies’ solid margins, recurring revenue, and leadership in high-growth areas, the majority of analysts are optimistic about the company’s shares.
Is It Wise to Invest in Agilent Technologies Stock in 2025?
Your investing objectives will determine if Agilent Technologies stock is a wise purchase.
✅ Purchase Agilent If You Want To:
-
Be exposed to innovations in healthcare and life sciences
-
A steady, mid-cap growth stock that has the potential to pay dividends
-
A business that does well in terms of margin and free cash flow
🚫 Avoid Agilent If You’re Concerned About:
-
Agilent’s high value in relation to profits
-
Short-term fluctuations in the economy can impact laboratory expenditures
-
Preference for a high dividend yield
Agilent is a good choice for anyone who want exposure to biotech tools and diagnostics without taking on too much risk, even if it may not be as high-flying as certain tech companies.
How to Purchase Stock in Agilent Technologies
Are you considering expanding your portfolio with Agilent Technologies stock? Here’s how:
-
Create a brokerage account with companies such as E*TRADE, Schwab, Robinhood, or Fidelity
-
Look up “A” as the ticker symbol on the NYSE
-
Depending on your risk tolerance and financial situation, choose how many shares to buy
-
Use market or limit orders to place your transaction
-
To remain informed, keep an eye on news and earnings updates
Dollar-cost averaging into Agilent Technologies stock may lessen the effect of short-term price swings for long-term investors.
In Conclusion, the Stock of Agilent Technologies in 2025
In 2025, Agilent Technologies’ stock is still a wise long-term investment due to its consistent revenue, life sciences innovation, and growing demand worldwide. Its steady financials, leadership in the sector, and development potential make it a solid choice for diverse portfolios, notwithstanding the dangers involved.
Agilent Technologies stock could be worth a deeper look if you’re looking for a firm that connects biotech innovation with steady industrial performance.